New immune plus anti-cancer pills to prevent liver cancer returning
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial studies anlotinib capsules plus penpulimab (an immune therapy) to help prevent hepatocellular carcinoma from coming back after it has been fully removed or fully destroyed. It may help high-risk patients lower the chance of recurrence and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old, and you can do normal daily activities with only mild limits (ECOG 0–1).
- Your liver cancer diagnosis was confirmed by tissue/cell testing, or you meet major liver-cancer diagnosis guidelines.
- You finished curative treatment (surgery or a single type of ablation like RFA or MWA) 4 to 12 weeks before starting the trial, and you fully recovered by 4 weeks before randomization.
- Your scans show no spread outside the liver and no leftover or returning cancer at the start.
- Your liver blood vessel involvement must be limited (no major portal vein blockages like Vp3/Vp4, and no vascular invasion in certain large veins).
- You have not had prior treatments like anti-angiogenic drugs, PD-1/PD-L1 immunotherapy, or other systemic chemotherapy after your cancer treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (Donafenib and Envafolimab) after surgery to lower the risk of liver cancer coming back in people who have high-risk features. It may help if you qualify based on your tumor(s) and overall health.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This study tests two different treatment combinations for liver cancer that cannot be removed with surgery. One group gets a treatment called TACE plus a pill combination, and the other gets TACE plus standard targeted immunotherapy. The goal is to see which approach works better.
This trial tests a personalized treatment plan for people whose advanced liver cancer (hepatocellular carcinoma) has progressed after initial targeted and immune therapy. It aims to find a next-step option tailored to your specific situation.
This study tests a combination of liver-directed chemotherapy (given through a small tube into the liver artery), targeted therapy, and an immunotherapy drug (a PD-1 inhibitor) to help prevent liver cancer from coming back after surgery. It is for people whose tumor showed microvascular invasion, which raises the risk of recurrence.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.